$INO: A 268% Pop, a Going-Concern Warning, and 91 Million Warrants Nobody Counted

At Friday's close, Inovio Pharmaceuticals was priced like a company the market had given up on. The stock fell 22% during the regular session to $0.60, a market value of roughly $62 million for the whole business, not far above the cash in its bank account. Hours later, after the closing bell, the FDA granted accelerated approval to VOCERYQ, Inovio's immunotherapy for recurrent respiratory papillomatosis. By Monday premarket the stock was trading near $2.22, up roughly 268% from that close.

Both moves were rational. Friday's selling was traders refusing to hold a binary event: October 30 was the FDA's decision deadline, this was the first product in Inovio's history to reach the finish line, and the agency says no to plenty of first attempts. Monday's buying is the other side of that coin. The approval is real, it is historic in a narrow but genuine sense, and it lands in a rare-disease market where a competitor has just spent a year proving that insurers will pay.

The question that matters now is not whether the approval is good news. It is what a company with a going-concern warning in its last quarterly filing does with a 268% gap, and what that means for everyone buying the pop this week.

What the FDA actually approved

Recurrent respiratory papillomatosis, RRP, is a rare disease caused by HPV types 6 and 11 in which wart-like growths repeatedly form in the airway, most often on the larynx. The growths are benign in the cancer sense and brutal in every practical sense: they obstruct breathing, destroy voices, and come back after removal. The standard of care for decades has been surgery, over and over. Severely affected patients go under the knife several times a year, every year. Inovio estimates at least 25,000 RRP patients in the United States.

VOCERYQ, previously known as INO-3107, is a plasmid DNA immunotherapy delivered by intramuscular injection with Inovio's CELLECTRA electroporation device, which uses brief electrical pulses to get the DNA into muscle cells. The cells then produce antigens that train T cells to attack HPV-6 and HPV-11 infected tissue. After a standard surgical clearing of visible papillomas, patients receive the therapy over a nine-week dosing regimen. It is the first plasmid DNA-based immunotherapy ever approved in the United States, per the FDA's own announcement, and the first approved product in Inovio's history.

The efficacy bar it cleared is worth stating precisely, because it is both impressive and modest. In the open-label trial of 32 adults that supported approval, all of whom needed at least two airway surgeries in the prior year, 27% of the efficacy population, 7 of 26 patients, required no surgery at all in the twelve months after treatment. Those were patients who had previously needed a median of 4.5 surgeries a year. The approval is accelerated, meaning conditional: Inovio must run a confirmatory trial, with a draft protocol due to the FDA by the end of 2026. If confirmation fails, accelerated approvals can be withdrawn.

Commercially, the company says VOCERYQ will be available to order and ship in roughly 60 days, which lands in early January, with the full field launch in the first quarter of 2027. H.C. Wainwright upgraded the stock to Buy on the news with a $5 price target, as reported by Investing.com on Monday.

The other half of the story is trading down 29%

What makes this a genuinely interesting setup rather than a routine biotech pop is that VOCERYQ is not entering an empty market. Precigen's Papzimeos, approved in August 2025 as the first-ever therapy for RRP, has spent the past year building exactly the commercial case Inovio now needs: Precigen reported $21.6 million of Papzimeos revenue in the first quarter of 2026 and $53.1 million in the second, with the company reporting more than 500 patients enrolled and near-complete payer coverage. For a disease this rare, that is a steep, real ramp, and it is why Precigen stock had more than doubled off its 52-week low.

On Friday night, Precigen became the read-through casualty. PGEN fell 27% in after-hours trading and was indicated down roughly 29% near $4.90 in Monday's premarket, against Friday's $6.94 close. The RRP market just went from monopoly to duopoly, and it did so four days before Precigen reports third-quarter results on Wednesday, November 4. That print now doubles as the single best data point anyone has on how big and how fast the RRP market really is, and it will move both stocks.

So the setup into this week: a newly approved product with a first-mover rival proving out the market, a stock that has repriced from $0.60 to above $2 in a single session, and a seller of last resort nobody is talking about on the way up. Because the most important document in this trade is not the FDA announcement. It is Inovio's own June 30 balance sheet, and what it says the company has to do next.

A free membership gets you every free article we publish at AlphaBriefing.com: Join AlphaBriefing.

The rest of this briefing is for paid members: the real share count including the 91 million warrants almost nobody buying today has counted, the going-concern clock and the financing move the last three raises say is coming, the November 4 Precigen read-through, and scenario-by-scenario price zones for the week ahead.

AlphaBriefing Paid gets you every investment thesis, scenario framework, and catalyst brief we publish, the analysis private intel clients pay four figures for, at a fraction of that.

Unlock the full briefing →